RESMED INC (RMD) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:RMD - US7611521078 - Common Stock
252.39 USD
+0.89 (+0.35%)
253.9 USD
+1.51 (+0.6%)
ChartMill assigns a Buy % Consensus number of 76% to RMD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 300.11. This target is 18.91% above the current price.
RMD was analyzed by 25 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about RMD.
In the previous month the buy percentage consensus was at a similar level.
RMD was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-31 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-31 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-13 | Wells Fargo | Initiate | Equal-Weight |
| 2025-09-18 | Citigroup | Initiate | Buy |
| 2025-08-01 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-01 | UBS | Maintains | Buy -> Buy |
| 2025-08-01 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Stifel | Maintains | Hold -> Hold |
| 2025-08-01 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-07-16 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-07-16 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-04-24 | UBS | Maintains | Buy -> Buy |
| 2025-04-24 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-04-24 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-04-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-24 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-04-21 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-03-05 | Stifel | Maintains | Hold -> Hold |
| 2025-03-05 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-01-31 | Needham | Reiterate | Hold -> Hold |
| 2025-01-31 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-01-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-01-31 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-01-10 | Piper Sandler | Initiate | Neutral |
| 2024-12-13 | Stifel | Initiate | Hold |
| 2024-10-25 | Needham | Reiterate | Hold |
RESMED INC / RMD FAQ
What is the average price target for RESMED INC (RMD) stock?
25 analysts have analysed RMD and the average price target is 300.12 USD. This implies a price increase of 18.91% is expected in the next year compared to the current price of 252.39.
Can you provide the consensus rating for RESMED INC stock?
The consensus rating for RESMED INC (RMD) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.